Alnylam Pharmaceuticals Stock Price - ALNY

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 90.58 0.00 0.00 0.00 90.58 19:00:00
Bid Price Ask Price Spread Spread % News
89.80 96.00 6.20 6.46% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Alnylam Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 10.10B 111.49M $ -761.50M -7.56 - 110.95M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Alnylam Pharmaceuticals News

Loading Messages....

Latest ALNY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALNY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week91.1493.9889.7591.59473,271-0.56-0.61%
1 Month81.9993.9880.9488.94581,9998.5910.48%
3 Months83.9993.9873.3283.75624,7446.597.85%
6 Months69.1293.9865.8177.61677,53521.4631.05%
1 Year68.3296.0860.2778.87787,33422.2632.58%
3 Years47.69153.98535.9887.03942,11042.8989.93%
5 Years99.54153.98531.3884.15904,502-8.96-9.0%

Alnylam Pharmaceuticals Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis, Alnylam has partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Your Recent History
Alnylam Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.